Heparin Prophylaxis Dosing for Antepartum Hospitalizations (HEPDOSE)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04635839 |
Recruitment Status :
Completed
First Posted : November 19, 2020
Last Update Posted : July 5, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pregnancy Related Antepartum DVT | Drug: Standard Dose of Unfractionated Heparin Drug: Gestational Age-Based Dose of Unfractionated Heparin | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 46 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | Randomized Control Trial of Unfractionated Heparin Thromboprophylaxis Dosing for Antepartum Hospitalizations |
Actual Study Start Date : | December 15, 2020 |
Actual Primary Completion Date : | March 31, 2022 |
Actual Study Completion Date : | May 1, 2022 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Standard Dosing
Standard dose of unfractionated heparin
|
Drug: Standard Dose of Unfractionated Heparin
5,000 units subcutaneous unfractionated heparin every 12 hours |
Active Comparator: Gestational Age-Based Dosing
Dose of unfractionated heparin based on trimester of pregnancy
|
Drug: Gestational Age-Based Dose of Unfractionated Heparin
|
- Elevated serum aPTT value above the normal range (> 36.2 seconds). [ Time Frame: From date of randomization through study completion, average 4 weeks ]Surrogate marker for whether or not the patient would be eligible for neuraxial anesthesia based on guidelines for neuraxial anesthesia in pregnant women receiving VTE prophylaxis
- Diagnosis of venous thromboembolism (pulmonary embolism and/or deep venous thromboembolism) [ Time Frame: From date of randomization up to 6 weeks postpartum ]
- Nonreceipt or delay of neuraxial anesthesia due to unfractionated heparin [ Time Frame: From date of randomization through study completion, average 4 weeks ]
- Receipt of general anesthesia due to unfractionated heparin [ Time Frame: From date of randomization through study completion, average 4 weeks ]
- Delay in timing of delivery due to unfractionated heparin [ Time Frame: From date of randomization through study completion, average 4 weeks ]
- Anti-Xa levels [ Time Frame: From date of randomization through study completion, average 4 weeks ]
- Number of times adjustment in unfractionated heparin dose made [ Time Frame: From date of randomization through study completion, average 4 weeks ]
- Mode of delivery [ Time Frame: From date of randomization until date of delivery ]
- Estimated blood loss from delivery [ Time Frame: From date of randomization until 6 weeks postpartum ]
- Receipt of blood transfusion [ Time Frame: From date of randomization until 6 weeks postpartum ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 50 Years (Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- At least 18 years of age
- Speak English or Spanish
- Antepartum admission for at least 72 hours at Ronald Reagan UCLA Medical Center
- Provides informed consent for study participation
Exclusion Criteria:
- Active or threatened antenatal bleeding
- Disseminated intravascular coagulation
- Risk of imminent delivery (delivery within 12 hours)
- Thrombocytopenia (platelet count < 100 x 109)
- Elevated baseline aPTT (> 36.2 seconds)
- Concern for hemolysis, elevated liver enzymes, low platelet count (HELLP) syndrome
- Congenital bleeding disorders (hemophilias)
- Receiving therapeutic or prophylactic anticoagulation (unfractionated heparin, low molecular weight heparin, oral anticoagulants) for alternative indication (e.g., acquired or inherited thrombophilia, history of VTE)
- History of heparin-induced thrombocytopenia (HIT)
- SARS-CoV-2 positive
- Cognitive impairment, psychiatric instability, or language barriers that limit their ability to provide informed consent
- Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04635839
United States, California | |
UCLA Medical Center | |
Los Angeles, California, United States, 90095 |
Responsible Party: | Thalia Wong, MD, Co-Principal Investigator, University of California, Los Angeles |
ClinicalTrials.gov Identifier: | NCT04635839 |
Other Study ID Numbers: |
20-001799 |
First Posted: | November 19, 2020 Key Record Dates |
Last Update Posted: | July 5, 2022 |
Last Verified: | June 2022 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Thromboprophylaxis Antepartum admission Heparin |
Heparin Calcium heparin Anticoagulants |
Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action |